(Q36611857)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

David Hedley

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

I Duran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

J Kortmansky

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

D Singh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

H Hirte

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

W Kocha

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

G Goss

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

L Le

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

A Oza

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

T Nicklee

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

J Ho

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

D Birle

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

G R Pond

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

D Arboine

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

J Dancey

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

S Aviel-Ronen

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

L L Siu

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

English

0 references

publication date

10 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

1148-1154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

20 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

mTOR-targeted therapy of cancer with rapamycin derivatives

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360568

Phase II trial of doxorubicin therapy for advanced islet cell carcinoma

20 September 2018

1 reference

12 December 2020

Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study

1 reference

12 December 2020

Doxorubicin, Streptozocin, and 5-Fluorouracil Chemotherapy for Patients with Metastatic Islet-Cell Carcinoma

1 reference

12 December 2020

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

1 reference

12 December 2020

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603419

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17031397%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

PubMed publication ID

17031397

1 reference